Using dodecyl N-acetylglucosaminide (GlcNAc-C12) as a saccharide primer, we investigated the biosynthetic changes of neolacto-series glycosphingolipids (GSLs) in mouse embryonal carcinoma F9 cells during differentiation induced by retinoic acid plus dibutyryl cyclic AMP (RA/dbcAMP). In the differentiated cells, the glycosylation of GlcNAc-C12 was greatly enhanced. The sugar compositions of glycosylated primers were assigned as Hex-GlcNAc, [Hex] 2 -GlcNAc, [Hex] 2 [HexNAc]-GlcNAc, and [NeuAc] [Hex]-GlcNAc by liquid chromatography-tandem mass spectrometry. The detection of augmented biosynthesis of endogenous sialylparagloboside indicated that [NeuAc] [Hex]-GlcNAc was predicted to be the non-reducing end trisaccharide of sialylparagloboside. The transcription of B3gnt5, B4galt1, Ggta1, Fut4 and St3gal6, encoding glycosyltransferases involved in the neolacto-series glycosphingolipids biosynthesis, was increased, whereas that of Fut9 and St6galI was decreased after RA/dbcAMP treatment. Furthermore, the sialyltransferase activity of ST3GalVI sialylating paragloboside was enhanced with the increase in St3gal6 expression. Since most stage-specific embryonic antigen-1 (SSEA-1) active determinants are carried by glycoproteins in F9 cells, the changes in glycolipid metabolism do not seem to be closely related to loss of cell surface SSEA-1 expression upon F9 differentiation. These results indicate that RA/dbcAMP treatment activates the biosynthesis of neolacto-series GSL and enhances sialylation of paragloboside in F9 cells with down-regulation of Fut9 expression.
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The nomenclature for glycosphingolipids follows the recommendations (21) of the IUPAC-IUB, and the ganglioside nomenclature of Svennerholm (22) was used.
Mouse embryonal carcinoma (EC) F9 cells derived from an induced teratocarcinoma are considered a suitable model for studying the mechanism of embryogenesis because their morphological appearance and biochemical properties are similar to those of discrete populations of cells which arise during early embryogenesis, and have the ability to differentiate into primitive endoderm-like cells under treatment with all-trans-RA either alone (1) or with dbcAMP (2). For example, the monoclonal antibody (Mab) MC480 recognizing SSEA-1 was raised against F9 cells and the expression of SSEA-1 in embryos can specify the certain stages of early development (3). SSEA-1, the antigenic determinant of which is Galb1,4(Fuca1,3)GlcNAcb1-R (4) is intensely expressed in F9 cells, but disappears with their differentiation in vitro. Besides the disappearance of SSEA-1, the expression of several carbohydrate antigens dramatically changes during the in vitro differentiation of F9 cells. The expression of I/i (5) antigens and Forssman antigen (6) is also down-regulated significantly, whereas that of SSEA-3 is up-regulated in F9 cells treated with retinoic acid (RA) or RA plus dibutyryl cyclic AMP (dbcAMP) (7).
Inokuchi and his colleagues reported that the overall expression of gangliosides was elevated in differentiated F9 cells (8) . In this study, we focused on changes in the expression of neolacto-series GSLs during the in vitro differentiation of F9 cells. Here we report that the biosynthesis of neolacto-series GSLs was also enhanced in F9 cells treated with RA/dbcAMP using the GlcNAc-C12 primer, a recently developed saccharide primer to synthesize neolacto-series oligosaccharides in cultured mammalian cells (9) , and that the expression of the genes responsible for the synthesis of neolaco-series GSLs was up-regulated, resulting in elevated levels of sialylparagloboside.
Materials and Methods
Cell culture and antibodies F9 cells were obtained from the Japanese Collection of Research Bioresources Cell Bank (Ibaraki-shi, Osaka-hu, Japan) and were cultured in Dulbecco's modified Eagle's medium (DMEM) (Sigma Chem, St Louis, MO, USA) containing 10% foetal bovine serum (FBS) (JRH Biosciences, Lenexa, KS, USA). The cells were induced to differentiate into primitive endoderm cells by the addition of 10 À7 M RA (Wako Pure Chem. Ind., Osaka, Japan) plus 10 3 M dbcAMP (Aldrich, Milwaukee, WI, USA) for 4 days. The anti-SSEA-1 Mab and both the anti-Dab2 Mab and anti-Oct3 Mab were purchased from Chemicon International (Temecula, CA, USA) and BD Biosciences (San Jose, CA, USA), respectively. The antisialylparagloboside Mab SPS established by Watarai et al. (10, 11) was used. The FITC-conjugated goat anti-mouse IgG þ M antibody and horseradish-peroxidase (HRP)-conjugated rabbit anti-mouse immunoglobulin antibody were purchased from Jackson Laboratory (West Grove, PA, USA) and DAKO A/S (Denmark), respectively.
Western analysis
Cells were homogenized in a lysis buffer (250 mM NaCl, 50 mM HEPES, pH 7.4 and 0.1% NP-40) by passing them through a 23-gauge needle and the homogenate was centrifuged at 15,000 rpm for 20 min at 4 C. The supernatant, the protein concentration of which was determined with a Bio-Rad Protein Assay (Bio-Rad Laboratories Inc., Hercules, CA, USA), was stored frozen prior to use. Ten micrograms of protein was separated by SDSPAGE and transferred to a PVDF membrane (Millipore Corp., Bedford, MA, USA). Non-specific binding sites were blocked with 5% skim milk in PBS. The blots were then incubated with the primary antibodies (diluted 1 : 1000) for 1.5 h, followed by HRP-conjugated goat anti-mouse immunoglobulin antibody (1 : 1000) for 1 h. The antibodies that bound to the membrane were visualized with the ECL Plus Western Blotting Detection system (GE Healthcare UK Ltd, Buckinghamshire, UK).
Flow cytometry
Cells were harvested and incubated with anti-SSEA-1 Mab for 1 h on ice. After being washed, the cells were incubated with FITC-conjugated goat anti-mouse IgG þ M (diluted 1 : 50) and analysed by flow cytometry (EPICS-XL, Beckmann-Coulter, Fullerton, CA, USA).
Incubation of F9 cells with the GlcNAc-C12 primer The GlcNAc-C12 primer was prepared as described (9) . Cells were incubated with the primer as reported by Yamagata and colleagues (12, 13) . Briefly, 2 Â 10 6 differentiated F9 cells (þF9) or undifferentiated F9 cells (ÀF9) were seeded into a 100-mm culture dish and cultured for 18 h. The cultured cells were washed with DMEM (Gibco, Grand Island, NY, USA) supplemented with D-(þ)-glucose (Sigma) and L-glutamine (Gibco) to remove FBS, and then further incubated with 50 mM of GlcNAc-C12 primer in DMEM (Gibco) supplemented with 10% knockout serum replacement (KSR) (Gibco)/D-(þ)-glucose/L-glutamine for 24 h. The glycosylated products secreted into the culture medium were collected with a solid phase extraction (SPE) cartridge, OASIS (Waters, Milford, MA, USA). The water-soluble compounds were removed with water, and the lipids were eluted with methanol. The eluates containing the glycosylated products were evapourated and dissolved in methanol for TLC analysis. For the analysis by liquid chromatographytandem mass spectrometry (LCMS/MS), the glycosylated products as obtained above were dissolved in 1 ml of chloroform/ methanol (C/M) (19/1, v/v) and adsorbed to an aminopropyl SPE cartridge, Discovery DSC-NH2 (SUPELCO, Bellefonte, PA, USA). After washing of the cartridge with chloroform, the products were eluted with 3% acetic acid/4% triethylamine (TEA) in methanol, and then with methanol. The eluates were passed through a cellulose acetate membrane filter, Cosmospin Filter H (pore size; 0.45 mm) (Nakalai Tesque Inc., Kyoto, Japan), evaporated, and dissolved in C/M (9 : 1).
LCMS/MS
Mass spectrometric analyses were performed using Electrospray ionization (ESI)/an ion trap type mass spectrometer (HCT-Ultra 11S, Bruker Daltonics, Billerica, MA, USA), coupled online by the Agilent 1,100 series Capillary LC system (Agilent Technologies, Wilmington, DE, USA) with ion extraction, separation and detection in both the positive and the negative ion modes. The glycosylated primers were loaded onto a 0. 
Glycolipid analysis
Lipids were extracted from the packed cell pellets with 2 ml of C/M (2/1, v/v) and then with 2 ml of C/M/W (7/11/2, v/v). Total extracts were combined and evaporated to dryness and then treated with 0.2 M KOH in methanol at 37 C for 2 h to saponify the phospholipids. The extracts were concentrated to 1/10 volume and mixed with 3 ml of water. Fatty acids were removed by mixing with hexane, and the solution was applied to a reverse-phase cartridge, Sep-Pak C18 (Waters). The cartridge was washed with 10 ml of water, and the lipids were eluted with 5 ml of methanol. The eluates were evapourated to dryness. To remove sialic acid residues, lipids were treated with 0.1 U of sialidase from Clostridium perfringens (Roche Applied Science, Mannheim Germany) in 50 mM sodium acetate buffer, pH 5.0 for 24 h at 37 C. Desialylated products were isolated using a Sep-Pak C18 cartridge.
TLC and TLC immunostaining
Glycolipids were separated on glass plates pre-coated with Silica Gel 60 (HPTLC plate, Merck, Darmstadt). The developing solvent system was a mixture of C/M/0.2% aqueous CaCl 2 (5 : 4 : 1, v/v/v). TLC immunostaining was performed according to a previously described method (14) . The plates were probed with Mab SPS-20 or anti-SSEA-1 Mab for 2 h, and then the HRP-conjugated rabbit anti-mouse immunoglobulins antibody (diluted 1 : 1000 in 1% BSA/ PBS) for 1 h. The antibodies that bound to the plates were visualized with ECL Plus Western Blotting Detection system. NeuAca2,3-linked paragloboside (IV 3 NeuAca-nLc 4 Cer) and NeuAca2,6-linked paragloboside (IV 6 NeuAca-nLc 4 Cer) purified from human O-type erythrocytes and human meconium, respectively, were used as control glycosphingolipids. III 3 Fuca-nLc 4 Cer was obtained by desialylation of sialylLewis X purchased from Wako Pure Chem. Industries Ltd. (Osaka, Japan).
Real-time RTPCR
Total RNA was isolated from cultured cells using the Qiagen RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. cDNA was synthesized from 5 mg of total RNA using a First-Strand cDNA Synthesis Kit (GE Healthcare Bio-Science Corp.). Real-time PCR was performed in 20 ml of a mixture consisting of 10 ml of SYBER Green Master mix (Applied Biosystems, CA, USA) and template cDNA using the ABI Prism 7900HT sequence detection systems. The levels of b-actin transcript were used for normalization of cDNA levels. Primer sequences for the selected genes encoding neolacto-series GSL synthases and b-actin are listed in Table I .
Paragloboside (neolactotetraosylceramide) a2,3sialyltransferase assay The sialyltransferase assay was performed in a reaction mixture containing 5 mM MgCl 2 , 0.3% (w/v) Triton CF-54, 100 mM sodium cacodylate buffer, pH 6.0, 3.9 mM CMP-NeuAc (Sigma), 3.7 kBq CMP-[ 14 C]NeuAc (NEC), 50 mg of cell lysates as the enzyme source, and 23.5 nmol of paragloboside analogue as an acceptor in a total volume of 50 ml. Paragloboside analogue was prepared by sialidase digestion of a2,3sialylparagloboside mimetic conjugate, which was synthesized by conjugation of NeuAca2,3Galb1,4GlcNAcb1, 3Galb1,4Glc (15) to 3-branched fatty-alkanol as a ceramide mimetic (16) , according to the procedure previously described (17) . The reaction mixture was incubated at 37 C for 3.5 h. The products were isolated using a Discovery DSC-18 cartridge (SUPELCO) and separated by TLC. The plate was exposed to an imaging plate for 3 days and the radioactivity on the plate was visualized with a BAS 2000 image analyser (Fuji film, Tokyo, Japan).
Results
Effect of RA/dcAMP treatment on in vitro differentiation of F9 cells To ascertain that RA/dcAMP treatment induces the differentiation of F9 cells in our culture system, we tested the expression of differentiation-related molecules during the culture in the presence of RA/ dbcAMP. Western analysis revealed that a marker of differentiation, Dab2, appeared in F9 cells on Day 2 and increased on Day 4, while a marker of undifferentiation, Oct3, decreased on Day 2 and completely disappeared on Day 4 (Fig. 1A) . Flow cytometric analysis showed that the expression of SSEA-1 in F9 cells dramatically decreased over 4 days in the presence of RA/dbcAMP (Fig. 1B) . The results indicate that RA/dbcAMP treatment can induce the differentiation of F9 cells in our culture system. GlcNAc-C12 does not affect RA/dbcAMP-mediated differentiation of F9 cells The ÀF9 and þF9 cells were further cultured in the absence or presence of 50 mM GlcNAc-C12 for 24 h. No apparent difference in morphology in the presence and absence of GlcNAc-C12 in the culture was observed in ÀF9 or þF9 cells (Fig. 2A) . The presence of GlcNAc-C12 affected neither the appearance of Dab2 nor disappearance of Oct3 induced by RA/dbcAMP (Fig. 2B) . The results clearly show that GlcNAc-C12 does not influence the differentiation of F9 cells mediated by RA/dcAMP treatment.
The glycosylation of GlcNAc-C12 primer in F9 cells The products elongated from the GlcNAc-C12 primer were recovered from ÀF9 and þF9 cells, and separated and detected by HPTLC with the orcinol or resorcinol reagent. Only a small part of the primer recovered from the ÀF9 cells was glycosylated, whereas a large quantity of the primer recovered from the þF9 cells was significantly glycosylated (indicated as G1, G2, G3 and G4 in Fig. 3A left panel) . Since G4 was stained to B3gnt5  NM_054052  aaaggaaagatagaacctaggggta  agacttttattgcttctttgtcttcc  B4galt1  NM_022305  tcgactatggcatctacgtca  gagcagcttagctcgattgaa  B4galt2  NM_017377  caatggctttcccaacga  cgtgagatcttcatcccagtc  B4galt3  NM_020579  agcttgcgtacggcatttat  tttgccctgttaaacgttcc  B4galt4  NM_019804  tcaaggtgaatggattctctaaca  ttttcattttatggagctcaacc  St3gal6  NM_018784  aagccagctttcgccaat  agctctgcacagaaatgggta  St6gal1  NM_145933  gtgtgccgtcgtgtcttct  ttaaacctcaggaccgcatc  Fut9  NM_010243  acctgtacccggctgctat  gatggagatgatcaccgagag  Fut4  NM_010242  caagcaatcttcccactcatt  tcgccatttatgtctcttcca  Ggta1  NM_010283  gaagacctcgcgctctca  gagcttctgtcgagctctgg  Actb  NM_007393  aaggccaaccgtgaaaagat  gtggtacgaccagaggcatac typical blue-purple colour like GM1 and the others were non-specifically stained to non-purple colour with resorcinol reagent, only G4 was thought to be sialylated ( Fig. 3A right panel) . A structural analysis of these glycosylated products was performed by LCMS/MS. The observed mass and the predicted composition of the products are listed in Table II . Figure 3B shows extracted ion chromatogram (EIC) of m/z at 653.8, 815.9 1,019.0 and
þ obtained from GlcNAc-C12 products and Fig. 3C shows the LC-ESI MS/MS spectra from the ion pointed by the arrow in each EIC. LCMS/MS analysis of the other ions did not demonstrate the presence of the characteristic GlcNAc-C12 product fragmentation pattern such as [Hex] [GlcNAc] (data not shown). The precursor ion pointed by the arrow in EIC of m/z 653.8 was assigned as Hex-GlcNAc-C12 (G1). That of m/z 815.9 was assigned as Hex-Hex-GlcNAc-C12 (G2) due to the presence of a peak at m/z 366.1 corresponding to
Since the informative data for structural analysis of that of m/z 1.019 could not be obtained from the MS/MS spectrum of [Hex] 2 [HexNAc] 1 GlcNAc-C12 (G3), the definitive branching site of HexNAc could not be deduced. The most probable structure of G3 is shown in Fig. 3C . That of m/z 945.0 was assigned as NeuAcHex-GlcNAc-C12 (G4) due to the presence of a peak at m/z 454.1 corresponding to
þ }. Since GlcNAc-C12 can be used as a primer for the elongation of lacto/neolacto-series GSLs, the carbohydrate moiety of Hex-Hex-GlcNAc-C12 and NeuAc-Hex-GlcNAc-C12 was thought to be the non-reducing end trisaccharide of IV 3 GalaLc 4 / nLc 4 Cer (neolactotetraosylceramide) and IV À of G1, G2, G3 and G4, respectively, were measured and normalized with the peak area of m/z 236.9 corresponding to isopropyl-b-D-thiogalactopyranoside, which was simultaneously run as an internal standard. The production of G1, G2, G3 and G4 increased 3.6, 2.2, 4.2 and 8.2-fold after differentiation, respectively (Fig. 3C) . , indicating that peak 3 is similar, but not the same to peak 2 (data not shown).
In order to obtain conclusive evidence for the endogenous expression of sialylparagloboside, we performed TLC immunostaining of mock-incubated and sialidase-digested F9 GSLs with Mab SPS-20. SPS-20 reacted to a2,3linked (Fig. 5 lane 1 express sialylparagloboside, and that the expression is augmented with differentiation.
Elevation of mRNA levels of glycosyltransferases involved in the neolacto-series GSL path way in RA/dbcAMP-treated F9 cells Next, we examined whether the expression of genes involved in the biosynthesis of neolacto-series GSLs is up-regulated in F9 cells after RA/dbcAMP-treatment using real-time RTPCR (Fig. 6A) . The expression of the gene (B3gnt5) encoding b-1,3-N-acetylglucosaminyltransferase 5, i.e. lactotriaosylceramide (Lc 3 Cer) synthase, which plays a key role in the synthesis of lacto/ neolacto-series carbohydrate chains on GSLs, was increased 4-fold (Fig. 6B upper) . In the neolacto-series biosynthetic cascade, we examined four genes (B4galt14) responsible for the formation of the Gal b1,4GlcNAc linkage. All the genes except B4galt2 were increased and the increase in B4galt1 was most prominent, 8-fold (Fig. 6B middle) . The up-regulation of B3gnt5 and B4galt1 expression indicates augmentation of the biosynthesis of neolacto-series GSLs in þF9 cells. The expression of Fut9, esponsible for the fucosylation of paragloboside to produce SSEA-1, and that of St6gal1, responsible for a2,6sialylation of paragloboside, was decreased to 1/10 and 1/2, respectively (Fig. 6B lower, right) . Fut4 responsible for the fucosylation of LacNAc-R on glycoproteins to produce SSEA-1 was increased 5-fold (data not shown). The expression of St3gal6 gene encoding a2,3sialyltransfer-ase VI for synthesizing IV 3 NeuAca-nLc 4 Cer and Ggta1 encoding a1,3galactosyltransferase for synthesizing IV 3 Gala-nLc 4 Cer was increased 18-and 17-fold, respectively (lower left).
Increase in a2,3Sialyltransferase activity towards paragloboside in RA/dbcAMP-treated F9 cells Since the increased production of IV 3 NeuAca-nLc 4 Cer seems to be due to the up-regulation of a2,3sialyl-transferase (ST3GalVI), we next examined the changes in activity of ST3GalVI during differentiation. The extracts of ÀF9 and þF9 were assayed for 
sialyltransferase activity using CMP-[ 14 C]NeuAc as a donor and paragloboside mimetic conjugates as acceptors. As shown in Fig. 7A , the lysate of þF9 (lane 6) sialylated the paragloboside analogue and the products co-migrated with the a2,3sialylpara-globoside analogue (lane 3), whereas that of ÀF9 (lane 5) sialylated the paragloboside analogue only a little. The amount of [ 14 C]NeuAc incorporated by þF9 lysates was 10.6-times that incorporated by ÀF9 cells (Fig. 7B) .
Expression of SSEA-1 epitope on glycoproteins and elevation of Fut4 gene expression in F9 cells Next, we examined whether SSEA-1 epitope is carried by glycoproteins or glycolipids in F9 cells. As presented in Fig. 8A , Western analysis clearly detected SSEA-1 in F9 cells with the 40%-decreased expression after in vitro differentiation (Fig. 8A) , whereas no SSEA-1 þ signals by TLC immunostaining of endogenous GSL (Fig. 8B) was observed, indicating that SSEA-1 epitope is mainly carried by glycoproteins, but not glycolipids. We further examined mRNA expression of Fut4 that is responsible for biosynthesis of SSEA-1 epitope on glycoproteins in F9 cells and observed 5-fold-increased transcription of Fut4 in F9 cells after RA/dbcAMP-treatment (Fig. 8C) . 
Increased sialylation of paragloboside in differentiated F9
of glycosphingolipids, except Gb3Cer and GlcCer, using their customized cDNA array focusing on genes responsible for the regulation of GSL metabolism, with a major increase in ganglioside content in differentiated F9 cells. Consistent with their observations, using the GlcNAc-C12 primer, we have detected elevated levels of lacto/neolacto-series GSLs, including sialylparagloboside, in F9 cells during RA/dbcAMP-mediated differentiation in this study. The enhanced biosynthesis of endogenous sialylparagloboside has also been confirmed. In parallel, real-time RTPCR showed an up-regulation of the gene expression for synthases of Lc 3 Cer, nLc 4 Cer, IV 3 NeuAca-nLc 4 Cer and IV 3 GalanLc 4 Cer. Furthermore, we confirmed the augmentation of the sialyltransferase activity of ST3GalVI responsible for the synthesis of sialylparagloboside in RA/dbcAMP-treated F9 cells. While most genes encoding glycosphingolipid synthases are up-regulated, the Fut9 and St6gal1 genes responsible for the synthesis of SSEA-1 and IV 6 NeuAca-nLc 4 Cer, respectively, are down-regulated. We summarized the up-regulated (grey solid arrow) and down-regulated (open arrow) expression of genes encoding neolacto-series glycosyltransferase in F9 cells differentiated by RA/dbcAMP treatment in Fig. 6A . Based on the above observations, we concluded that RA/dbcAMP treatment activates the biosynthetic pathway producing neolacto-series GSLs and enhances sialylation and galactosylation of paragloboside in F9 cells in the absence of Fut9 and St6gal1 up-regulation, resulting in an increase of sialylparagloboside. 
